Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ALVOBullishCorporate Developmentsnews

High materiality8/10

Alvotech secures $75M loan, $165M equity raise to boost biosimilars growth

Jul 1, 2026, 4:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Stronger liquidity and validated strategic progress (FDA milestones, sizable equity and debt) can lift ALVO's risk profile and support higher multiple attribution, particularly as the company advances multiple biosimilar programs and expands globally.

AI summary

What happened, with direct paths to the underlying reporting

Alvotech announced an amendment to its credit agreement for up to $75 million in additional term loans, bringing total available capital to $240 million after a $165 million equity raise in June 2026. The financing supports its biosimilars pipeline, including FDA BLA resubmissions and an Entyvio biosimilar, and funds expanded global commercial operations and launches.

Alvotech adds $75M term loan; total new capital now $240M.
Follows $165M equity raise announced June 18, 2026.
Loan bears 12.50% interest; maturity December 31, 2027.
Funds to support R&D pipeline, product launches, and global expansion.
FDA resubmission of BLAs and Entyvio biosimilar BLA acceptance; ~30 biosimilars in development.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Alvotech secures $75M loan, $165M equity raise to boost biosimilars growth

Alvotech Shares Plunge 33% After FDA Flags Issues

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug